Selected Publications
Ban-Ami, R, Wang, QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJJ, Janne PA, Bardeesy N, Stanger B, O'Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BM: Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer Gut 7 (73): 639-648,2024.
Brown TJ, Yablonovitch A, Till JE, Yen J, Kiedrowski LA, Hood R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Carpenter EL, Nathanson K, Domchek SM, Reiss KA.: The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib Clinical Cancer Research
29 (24): 5207-5216,2023.
Chapin WJ, Hwang WT, Mamtani R, O'Hara MH: Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC) American Society of Clinical Oncology Annual Meeting, Chicago, IL. 41 (suppl 16): abstract 3574,2023.
O'Hara MH, Wattenberg MM, Garrido-Laguna I, O'Reilly EM, Yellin MJ, Keler T, Gargano MA, Niles N, Drees J, Bose N, Iglesias JL, Beatty GL: A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL. 41 (suppl 16): TPS4201,2023.
Brown TJ, Reiss KA, O'Hara MH: Advancements in Systemic Therapy for Pancreatic Cancer American Society for Clinical Oncology Educational Book 43 : e397082. ,2023.
Wiess S, Speicher LA, Brozena LJ, Xu J, Luke RA, Rivera JI, Aprelev P, Nunez-Cruz S, Milone MC, Sterman DH, O'Hara MH, Haas AR, Tanyi JL, Johnson LA: A Phase 1 KIR-CAR Clinical Trial for Patients with Cholangiocarcinoma,
Mesothelioma, or Ovarian Cancers Cholangiocarcinoma Foundation Annual Meeting, Salt lake City, Utah : 2023.
Cannas S, Till JE, Kim K, LaRiviere MJ, Vollmer CM, Eads JR, Karasic TB, O'Dwyer PJ, Schneider CJ, Teitelbaum UR, Reiss Binder KA, O'Hara MH, Ross DT, McGregor K, Bornemann-Kolatszki K, Schutz E, Beck J, Carpenter EL: Liquid biopsy signature combining copy number instability and mutant KRAS
detection is associated with survival for patients with metastatic pancreatic cancer AACR Annual meeting, Orlando, FL : 2023.
Lyman JP, Cabanski CR, Maddock S, Wolff RA, Wainberg ZA, Ko AH, Rahma O, Fisher G, Gabriel PE, Doucette A, Zheng-Lin B, Maloy MA, Dugan U, Fairchild J, Spasic M, O'Donnell-Tormey J, Vonderheide RH, O'Hara MH, O'Reilly EM: Clinical Benefit of Granulocyte-Colony Stimulating Factor (GCSF) Use During Chemoimmunotherapy Treatment for Metastatic Pancreatic Adenocarcinoma (mPDAC) American Society of Clinical Oncology GI Symposium, San Francisco, CA : 2023.
Sanborn RE, Gabrail N, Carneiro B, O'Hara MH, Bordoni R, Gordon M, Khalil D, Hauke RJ, Taglienti C, Rogalski M, Styles. R, Alvarado D, Maurer D, Malenchek L, Murphy M, Vitale L, Hawthorne T, Morani P, Thomas L, Keler T, Yellin M: Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab Society for Immunotherapy for Cancer Annual Meeting, Boston, MA : 2022 .
Friedman CF, Carvajal RC, Davar D, Castanon E, Ascierto PA, Calvo E, O'Hara MH, Powell S, Shapira-Frommer R, Garralda E, Renouf DJ, Perets R, Yunan M, Ravindran P, Hammell A, O'Brien S, Xu, K, Wilson N, Jhatakia A, Mukhopadhyay A, Gutierrez M: Phase 1/2a study of the novel nonfucosylated anti-CTLA4 monoclonal antibody BMS-986218 +/- nivolumab in advanced solid tumors: Part 1 results Society for Immunotherapy of Cancer Annual Meeting, Boston, MA : 2022.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-360-0735
Patient appointments: 800-789-7366